MADISON, Wis. , Oct. 2, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has a 510(k) pending for an online adaptive therapy option*, Cenos™, for its Radixact ® System. The solution was unveiled, in partnership with Limbus AI, at the 2023 ASTRO ( American
Large classrooms and a hybrid, in-person/remote connection option will make it easier for more care providers to remain current on best practices and innovations in radiation therapy New center is part of the company's comprehensive education program which also includes on-site training, online
Accuray develops, manufactures and sells radiation oncology systems that make cancer treatments shorter, safer, smarter and more effective. Accuray provides treatment delivery technologies that set the industry standard for precision and cover the full range of radiation therapy and radiosurgery treatments, as well as fully integrated software solutions that drive faster, smarter treatment planning.